Rapamycin in Cerebral Cavernous Malformations: What Doses to Test in Mice and Humans
{{output}}
Cerebral cavernous malformations (CCMs) are hemorrhagic neurovascular lesions that affect more than 1 million people in the United States. Rapamycin inhibits CCM development and bleeding in murine models. The appropriate dosage to modify disease phenotype rema... ...
